Clinical outcomes after switch to mTOR inhibitors in kidney transplant recipients
PDF (Español (España))
PDF
HTML (Español (España))

Keywords

Kidney transplantation
immunosuppression
sirolimus
everolimus
renal insufficiency
chronic

How to Cite

1.
Mesa Ramirez L, Gómez Vega JC, Pino - Escobar J, Rivera LM, Manzi -Tarapues E, Posada - Chavez JG, Schweineberg - López J, Duran - Rebolledo CE, Villegas - Otálora JI, Serrano Ardila OJ, Caicedo-Rusca LA. Clinical outcomes after switch to mTOR inhibitors in kidney transplant recipients. Rev. Colomb. Nefrol. [Internet]. 2018 Jan. 18 [cited 2022 Nov. 26];5(1):26-35. Available from: https://revistanefrologia.org/index.php/rcn/article/view/290

Abstract

Introduction: mTOR inhibitors Sirolimus and Everolimus are an alternative for inmunosuppression in renal transplant recipients. The aim of the study was to describe the experience of patients with switch to mTOR inhibitors, followed up for more than five years.

Materials and methods: Patients with renal transplantation from 1995 to 2013, who had indication of calcineurin inhibitor (CNI) withdrawl after the third month post-transplant were included. All patients underwent renal biopsy prior to conversion. No patient had a diagnosis of chronic nephtopathy, IFTA>40 % or proteinuria >350mg/24h. A descriptive analysis for all variables was devoloped. Kaplan-Meier method was used for the patient`s and graft survival and graft rejection incidence.

Results: From 1273 renal transplants, the switch from CNI to mTOR inhibitors was performed in 166 (13 %), 78 % (n=129) were switched to Sirolimus. 12,6 % of the patients lost graft function and 4,2 % (n=7) died. 37% had mTOR inhibitors withdrawal, and the major cause was pathologic proteinuria. The incidence of graft rejection after switching to mTOR inhibitors was 9,6 %. The one and five year graf survival was 96,6 % and 83,5 %. The patient survival at one and five years was 98 % and 97 %.

Conclusions: The use of mTOR inhibitors drugs appears to be safe in the managgement of specific renal transplant recipients, with a low rejection rate and good survival.

https://doi.org/10.22265/acnef.5.2.290
PDF (Español (España))
PDF
HTML (Español (España))

References

1. Cuenta de Alto Costo. Situación de la enfermedad renal crónica, hipertensión arterial y diabetes mellitus, 2015. Bogotá: Fondo Colombiano de enfermedades alto costo; 2015.

2. Acosta O, Arias Y, García S, Salinas M, Torres E, Osorio L. Informe anual red de donacion y trasplante en Colombia. [Internet] 2016 [accedido 23 Jun 2017]. Disponible en: http://www.ins.gov.co/lineas-de-accion/Red-Nacional-Laboratorios/Estadsticas/InformeRed de Donación y Trasplante 2015.pdf

3. Dávila FA, Pareja MJ, Rodríguez ES, Fajardo WR, Luna RD, Flórez KV. Análisis de supervivencia del trasplante renal (cohorte retrospectiva). Rol Colomb. 2017;26(1):12-16. http://doi.org/10.1016/j.uroco.2016.03.005

4. Méndez Durán A, Fermín Piñón JG. Mortalidad en ingresos a diálisis peritoneal. Estudio comparativo de la modalidad continua ambulatoria y automatizada Rev Fac Med UNAM. 2009;52(5):199-203.

5. Montero Benzo R, Vicente Guillén R. Tratado de transplante de órganos, españa. Madrid: Arán Ediciones; 2006.

6. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG. Identifying Specific Causes of Kidney Allograft Loss. Am J Transplant. 2009;9(3):527-535.
http://doi.org/10.1111/j.1600-6143.2008.02519.x

7. Graham RM. Cyclosporine: Mechanisms of Action and Toxicity. Cleve Clin J Med. 1994;61(4); 308-313.

8. de Mattos AM, Olayaei AJ, Bennett WM. Nephrotoxicity of Immunosuppressive Drugs: Long-Term Consequences and Challenges for the Future. Am J Kidney Dis. 2000;35(2):333-346.

9. Riva N, Cáceres Guido P, Rousseau M, Dip M, Monteverde M, Imventarza O, et al. Farmacovigilancia de inhibidores de calcineurina en trasplante renal y hepático pediátrico. Farm Hosp. 2013;37(6):441-449. http://doi.org/10.7399/FH.2013.37.6.778

10. Andrés A, Polanco N, González E. Optimización de la función renal con inhibidores de mTOR. Nefrología. 2011;2(3):10-18.
http://doi.org/10.3265/NefrologiaSuplementoExtraordinario.pre2011.Jun.10992

11. Rodríguez Pérez JC. El papel de los inhibidores de mTOR en las enfermedades renales. Nefrología. 2011;31(3):251-255. http://doi.org/10.3265/Nefrologia.pre2011.Apr.10947

12. Franco-Esteve A, Tordera D, de la Sen ML, Jiménez L, Mas P, Muñoz C, Olivares J. mTOR Inhibitor Monotherapy. A Good Treatment Choice in Renal Transplantation?. Nefrología. 2012;32(5):631-638. http://doi.org10.3265/Nefrologia.pre2012.Jun.11314

13. Lebranchu Y, Snanoudj R, Toupance O, Weestel PF, Hurault de Ligny B, Buchler M, et al. Five-Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The SPIESSER Study. Am J Transplant. 2012;12(7):1801-1810.
http://doi.org/10.1111/j.1600-6143.2012.04036.x

14. Letavernier E, Legendre C. mToR Inhibitors-Induced Proteinuria: Mechanisms, Significance, and Management. Transplant Rev (Orlando). 2008;22(2):125-130. http://doi.org/10.1016/j.trre.2007.12.001

15. Diekmann F, Andrés A, Oppenheimer F. mTOR Inhibitor-Associated Proteinuria in Kidney Transplant Recipients. Transplant Rev (Orlando). 2012;26(1):27-9.
http://doi.org/10.1016/j.trre.2007.12.00110.1016/j.trre.2011.10.003

16. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(Suppl 3):S1-S157. http://doi.org/10.1111/j.1600-6143.2009.02834.x

17. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
http://doi.org/10.2337 / dc09-S013

18. Soles K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions. Am J Transplant. 2008;8(4):753-760.
http://doi.org/10.1111/j.1600-6143.2008.02159.x

19. Montero C, Aldana G, Torres R. 24-Month Monitoring to a Late Conversion From a Calcineurin Inhibitor Regime to Everolimus in Kidney Transplant Recipients. Rev Colomb Nefrol. 2015;2(2):78-95. http://doi.org/10.22265/acnef.2.2.209

20. Lieberthal W, Levine JS. The Role of the Mammalian Target of Rapamycin (mTOR) in Renal Disease. J Am Soc Nephrol. 2009;20(12):2493-2502. http://doi.org/10.1681/ASN.2008111186

21. Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group. Comparison of Sirolimus Plus Tacrolimus Versus Sirolimus Plus Cyclosporine in High-Risk Renal Allograft Recipients: Results from an Open-Label, Randomized Trial. Transplantation. 2008;86(9):1187-1195.
http://doi.org/10.1097/TP.0b013e318187bab0

22. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of Sirolimus on Malignancy and Survival after Kidney Transplantation: Systematic Review and Meta-Analysis of Individual Patient Data. BMJ. 2014;349. http://doi.org/10.1136/bmj.g6679

23. El-Agroudy AE, Alarrayed SM, Al-Ghareeb SM, Farid E, Alhelow H, Abdulla S. Efficacy and Safety of Early Tacrolimus Conversion to Sirolimus after Kidney Transplantation: Long-Term Results of a Prospective Randomized Study. Indian J Nephrol. 2017;27(1):28-36.
http://doi.org/10.4103/0971-4065.176146

24. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter Randomized Trial Comparing Tacrolimus (FK506) and Cyclosporine in the Prevention of Renal Allograft Rejection: A Report of the European Tacrolimus Multicenter Renal Study Group. Transplantation.1997;64(3):436-443.

25. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin Inhibits Primary and Metastatic Tumor Growth by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor. Nat Med. 2002;8(2):128-135.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.